SCHEMBL6497671

SCHEMBL6497671

CN(C)c1ccc(-c2cc(Cl)ccc2C(=O)Nc2ccc(NCCc3ccccn3)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.48
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
CYP3A4 P08684 1/20 0.44
GCGR P47871 5/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPT P10636 1/20 0.43
MCL1 Q07820 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CTNNB1 P35222 1/20 0.43
TCF7L2 Q9NQB0 1/20 0.43
KDM4E B2RXH2 2/20 0.42
HPGD P15428 2/20 0.42
GAA P10253 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
USP28 Q96RU2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
EGFR P00533 1/20 0.42
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497806 0.92 CNR1 (0.57) CNR1GCGRSMN1; SMN2CTNNB1TCF7L2
SCHEMBL6489454 0.91 MAOA (0.46) MAOAMAOBCYP3A4GCGRSMN1; SMN2
SCHEMBL6496376 0.90 CNR1 (0.51) CNR1GCGRSMN1; SMN2CTNNB1TCF7L2
SCHEMBL6792320 0.90 MAOA (0.50) CNR1MAOAMAOBCYP3A4SMN1; SMN2
SCHEMBL6501757 0.87 GCGR (0.54) CNR1GCGRSMN1; SMN2CTNNB1TCF7L2
SCHEMBL6501182 0.86 SMO (0.53) CNR1GCGRKDM4EGAA
SCHEMBL6647277 0.86 CNR1 (0.53) CNR1SMN1; SMN2MAPTCTNNB1TCF7L2
SCHEMBL6646787 0.86 CNR1 (0.53) CNR1SMN1; SMN2CTNNB1TCF7L2KDM4E
SCHEMBL6488474 0.86 CNR1 (0.57) CNR1GCGRSMN1; SMN2CTNNB1TCF7L2
SCHEMBL6502872 0.85 CYP3A4 (0.46) MAOAMAOBCYP3A4SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 CNR1 102/4885MAOA 258/4885MAOB 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.